Jasbir Seehra

CIK: 0001732369

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (14.3%)

Position reduction

Option Exercises (M)2 (28.6%)

Derivative conversions

Awards (A)4 (57.1%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KROS

Keros Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

KROS
Keros Therapeutics, Inc.
Apr 2, 2026
Exercise(M)
Direct
55K shares at avg. $0.30$17K
KROS
Keros Therapeutics, Inc.
Feb 24, 2026
Award(A)
Employee Stock Option (Right to Buy)
Direct
217K shares-
KROS
Keros Therapeutics, Inc.
Feb 24, 2026
Award(A)
Employee Stock Option (right to buy)
Direct
100K shares-
KROS
Keros Therapeutics, Inc.
Feb 19, 2026
Sale(S)
Direct
7K shares at avg. $16.17$113K
KROS
Keros Therapeutics, Inc.
Jan 7, 2026
Award(A)
Employee Stock Option (right to buy)
Direct
62.5K shares-
KROS
Keros Therapeutics, Inc.
Sep 3, 2025
Award(A)
Direct
90.5K shares-
KROS
Keros Therapeutics, Inc.
Apr 4, 2025
Exercise(M)
Direct
49.4K shares at avg. $0.30$15K

		Type	Shares	Price		Ownership
Apr 2, 2026	KROS Keros Therapeutics, Inc.	Exercise(M)	55,000	$0.30	$16,500	Direct
Feb 24, 2026	KROS Keros Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	217,000	-	-	Direct
Feb 24, 2026	KROS Keros Therapeutics, Inc.	Award(A) Employee Stock Option (right to buy)	100,000	-	-	Direct
Feb 19, 2026	KROS Keros Therapeutics, Inc.	Sale(S)	7,015	$16.17	$113,433	Direct
Jan 7, 2026	KROS Keros Therapeutics, Inc.	Award(A) Employee Stock Option (right to buy)	62,500	-	-	Direct
Sep 3, 2025	KROS Keros Therapeutics, Inc.	Award(A)	90,500	-	-	Direct
Apr 4, 2025	KROS Keros Therapeutics, Inc.	Exercise(M)	49,367	$0.30	$14,810	Direct

1-7 of 7 transactions

About Seehra Jasbir

Seehra Jasbir (SEC CIK 0001732369) files insider reports with the SEC as CHIEF EXECUTIVE OFFICER of Keros Therapeutics, Inc. (KROS).

Signal8 holds 6 ownership filings by Seehra Jasbir, all Form 4s, filed between Apr 7, 2025 and Apr 6, 2026. Those filings report 7 transactions, from Apr 4, 2025 to Apr 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Seehra Jasbir's filings is in LEXINGTON, MA.

Recent filings by Seehra Jasbir

Apr 2, 2026: Option exercise of KROS shares (Form 4, code M).
Feb 24, 2026: Grants or awards of KROS derivative securities (2 lines, Form 4, code A).
Feb 19, 2026: Open-market sale of KROS shares (Form 4, code S).
Jan 7, 2026: Grant or award of KROS derivative securities (Form 4, code A).
Sep 3, 2025: Grant or award of KROS shares (Form 4, code A).

Other insiders filing for Keros Therapeutics, Inc. (KROS)

Tanini Annita, Corp. Controller & VP, Finance
Lerner Lorena Raquel, Chief Scientific Officer
Cho Esther, Chief Legal Officer
Newton Charles W., Director
BIENAIME JEAN JACQUES, Director
Prener Anne, Director

How to read Form 4 transaction codes